Abstract

Among women, endometrial carcinoma is by far the most common form of gynecological cancer. The molecular processes underlying the development and progression of endometrial cancer are not well understood, despite substantial breakthroughs in detection and therapy. This research paper aims to explore the role of Integrin beta-3 (ITGB3) and HOX genes in endometrial cancer, shedding light on their potential as biomarkers and therapeutic targets. Among the many biological activities that integrin beta-3 (ITGB3) contributes to include cell proliferation, migration, and angiogenesis, to name a few. Numerous studies have implicated ITGB3 in tumor development and metastasis. There is evidence that ITGB3 has a role in the development and prognosis of endometrial cancer due to its altered expression and dysregulation. The homeobox gene (HOX) family encodes transcription factors necessary for proper cell differentiation and development at all stages of embryonic life. Endometrial cancer is only one of several types of cancer linked to HOX gene dysregulation. The study provides an overview of the specific HOX genes involved in endometrial cancer and their functional significance in disease progression. It also discusses the potential utility of HOX genes as diagnostic markers and therapeutic targets in endometrial cancer management.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call